BIT doesn't have the time (or money) for another phase 2 trial, but yes I think your assessment is correct on what is needed. Without evidence in humans of a direct effect on HIV at a dose the patients can handle they are not going to able to move into a phase 3 trial.
On top of this they need long term side effect data and data on how quickly the virus develops resistance to BIT225.
I wouldn't be too worried about Abixav though - their HIV drug is going nowhere either.
$10 Billion Deal, page-1291
-
- There are more pages in this discussion • 11,977 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.0¢ |
Change
-0.003(9.09%) |
Mkt cap ! $27.06M | |||
| Open | High | Low | Value | Volume |
| 3.3¢ | 3.4¢ | 3.0¢ | $32.26K | 1.016M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 720804 | 3.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.1¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| BIT (ASX) Chart |